This study compared planktonic MIC values to minimum biofilm eradication concentrations (MBEC) for multiple antimicrobials tested against *Pseudomonas aeruginosa* isolates from cystic fibrosis (CF) patients, using a peg-based biofilm model.
All tested antimicrobials showed significantly reduced susceptibility under biofilm vs. planktonic conditions (p < 0.0001); no isolate had an MBEC lower than its MIC. Ciprofloxacin, amikacin, tobramycin, and azithromycin retained relatively better biofilm-state activity, while beta-lactams, levofloxacin, and colistin showed the greatest loss of efficacy.
Full text was inaccessible; sample size, specific MIC/MBEC values, and isolate count are not reported here. The peg-based biofilm model may not fully replicate in vivo CF lung biofilm conditions. Findings are specific to CF-derived isolates and may not generalize to other patient populations.
Standard MIC-based susceptibility testing may substantially underestimate the antibiotic concentrations needed to eradicate *P. aeruginosa* biofilms in CF patients. Consider biofilm-based susceptibility testing (MBEC) as a complementary tool when managing chronic CF lung infections, particularly when beta-lactams, levofloxacin, or colistin are being considered.
Explore related topics
